English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/49816
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


p21Cip1 Confers resistance to imatinib in human chronic myeloid leukemia cells

AuthorsFerrándiz, Nuria ; Caraballo, Juan M. ; Albajar, Marta ; Blanco, Rosa ; Delgado, M. Dolores ; León, Javier
Chronic myeloid leukemia
Issue Date1-Jun-2010
CitationCancer Letters 292(1): 133-139 (2010)
AbstractImatinib is a Bcr-Abl inhibitor used as first-line therapy of chronic myeloid leukemia (CML). p21Cip1, initially described as a cell cycle inhibitor, also protects from apoptosis in some models. We describe that imatinib down-regulates p21Cip1 expression in CML cells. Using K562 cells with inducible p21 expression and transient transfections we found that p21 confers partial resistance to imatinib-induced apoptosis. This protection is not related to the G2-arrest provoked by p21, a decrease in the imatinib activity against Bcr-Abl or a cytoplasmic localization of p21. The results suggest an involvement of p21Cip1 in the response to imatinib in CML.
DescriptionEl pdf del artículo es la versión pre-print.-- et al.
Publisher version (URL)http://dx.doi.org/10.1016/j.canlet.2009.11.017
Appears in Collections:(IBBTEC) Artículos
Files in This Item:
File Description SizeFormat 
p21Cip1.pdf300,64 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.